Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction

Trial ID or NCT#



recruiting iconRECRUITING


We intend, with this study, to prove that blocking the molecular mechanisms whose blockade prevents VIDD in animals, will indeed prevent the development of VIDD in humans as well. We believe that this evidence will serve as the required basis for proceeding with large, ICU-based clinical trial(s) of a drug to prevent VIDD.

Official Title

A Clinical Trial of JAK Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Patients undergoing esophagectomy
Exclusion Criteria:
  1. - Patients with more than mild pulmonary dysfunction - Patients with any neuromuscular disease that might compromise diaphragm function - Patients with abnormal liver or kidney function - Patients taking any immunosuppressant medication (including prednisone) or antifungal medications - History of tuberculosis - Weight loss of >5% of body weight over previous 6 months - Pregnancy


Joseph Shrager
Joseph Shrager
Thoracic surgeon, Surgical oncologist
Professor of Cardiothoracic Surgery

Contact us to find out if this trial is right for you.


Study Team